ADAP Stock Price, Adaptimmune Therapeutics Plc Quote, Chart

Market Summary

USD0.470.00

Market Closed

0.00%

ADAP Alerts

Losses in recent quarter

ADAP Stock Price

View Fullscreen

ADAP RSI Chart

ADAP Alerts

Losses in recent quarter

ADAP Valuation

Market Cap

639.9M

Price/Earnings (Trailing)

-6.72

Price/Sales (Trailing)

9

EV/EBITDA

-6.49

Price/Free Cashflow

-4.87

ADAP Price/Sales (Trailing)

ADAP Profitability

EBT Margin

-124.81%

Return on Equity

-71.87%

Return on Assets

-26.54%

Free Cashflow Yield

-20.54%

ADAP Fundamentals

ADAP Revenue

Revenue (TTM)

71.1M

Revenue Y/Y

4.45%

Revenue Q/Q

42.67%

ADAP Earnings

Earnings (TTM)

-95.2M

Earnings Y/Y

-10.09%

Earnings Q/Q

-113.2%

Price Action

Last 7 days

11.6%

Last 30 days

-12.7%

Last 90 days

-40%

Trailing 12 Months

-78.2%

How does ADAP drawdown profile look like?

ADAP Financial Health

Current Ratio

3.44

ADAP Investor Care

Shares Dilution (1Y)

38.55%

Diluted EPS (TTM)

-0.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	71.2M	70.8M	71.1M	0
2022	9.3M	11.7M	17.5M	27.1M
2021	3.6M	6.2M	6.2M	6.1M
2020	1.7M	2.2M	3.2M	4.0M
2019	44.9M	30.3M	15.7M	1.1M
2018	43.2M	48.7M	62.3M	59.5M
2017	14.1M	17.3M	42.1M	37.8M
2016	14.7M	12.2M	9.7M	14.2M
2015	7.6M	9.9M	12.2M	14.5M
2014	0	825.0K	3.1M	5.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for ADAP

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 01, 2023	rawcliffe adrian	sold	-1,874	0.78	-2,403	chief executive officer
Aug 01, 2023	lunger john	sold	-2,803	0.9056	-3,096	chief patient supply officer
Jul 10, 2023	menzel garry e	sold	-43,447	0.9108	-47,702	-
Jun 27, 2023	rawcliffe adrian	sold	-2,146	0.92	-2,333	chief executive officer
Jun 01, 2023	menzel garry e	acquired	-	-	209,931	-
Jun 01, 2023	menzel garry e	acquired	-	-	401,293	-
Jan 31, 2023	piccina cintia	sold	-22,229	1.8696	-11,890	chief commercial officer
Jan 17, 2023	bertrand william c jr	sold	-8,249	1.858	-4,440	chief operating officer
Jan 17, 2023	rawcliffe adrian	sold	-18,685	1.858	-10,057	chief executive officer
Jan 17, 2023	lunger john	sold	-8,249	1.858	-4,440	chief patient supply officer

Which funds bought or sold ADAP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Nov 15, 2023	CAPTRUST FINANCIAL ADVISORS	unchanged	-	-3,179	17,101	-%
Nov 15, 2023	GSA CAPITAL PARTNERS LLP	sold off	-100	-32,000	-	-%
Nov 15, 2023	Beaird Harris Wealth Management, LLC	unchanged	-	-14.00	72.00	-%
Nov 15, 2023	MORGAN STANLEY	reduced	-1.24	-321,335	1,600,050	-%
Nov 14, 2023	Matrix Capital Management Company, LP	unchanged	-	-5,651,260	30,399,900	0.36%
Nov 14, 2023	TWO SIGMA INVESTMENTS, LP	reduced	-45.47	-55,053	46,858	-%
Nov 14, 2023	LAZARD ASSET MANAGEMENT LLC	added	4.44	-	3,000	-%
Nov 14, 2023	TANG CAPITAL MANAGEMENT LLC	added	5.72	-490,471	4,030,220	0.57%
Nov 14, 2023	MPM ASSET MANAGEMENT LLC	unchanged	-	-911,630	4,903,940	2.63%
Nov 14, 2023	CSS LLC/IL	unchanged	-	-13,151	70,748	-%

Latest Funds Activity

Are funds buying ADAP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ADAP

No. of Funds

Schedule 13G FIlings of Adaptimmune Therapeutics Plc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 08, 2023	long focus capital management, llc	2.9%	6,582,798	SC 13G
Jul 10, 2023	matrix capital management company, lp	17.29%	233,845,110	SC 13G/A
Mar 30, 2023	new enterprise associates 14, l.p.	10.3%	102,478,672	SC 13D/A
Feb 14, 2023	pfm health sciences, lp	3.0%	6	SC 13G/A
Feb 13, 2023	capital world investors	0.0%	0	SC 13G/A
Jan 18, 2023	baillie gifford & co	10.48%	103,019,634	SC 13G/A
Dec 02, 2022	baillie gifford & co	10.44%	102,618,552	SC 13G/A
May 09, 2022	pfm health sciences, lp	5.8%	6	SC 13G
Jan 18, 2022	baillie gifford & co	8.81%	82,538,112	SC 13G/A
Feb 16, 2021	baker bros. advisors lp	6.4%	58,985,262	SC 13G

Recent SEC filings of Adaptimmune Therapeutics Plc

View All Filings

Date Filed	Form Type	Document
Nov 14, 2023	8-K	Current Report
Nov 08, 2023	SC 13G	Major Ownership Report
Nov 08, 2023	8-K	Current Report
Nov 08, 2023	10-Q	Quarterly Report
Nov 03, 2023	8-K	Current Report
Nov 01, 2023	3	Insider Trading
Oct 31, 2023	8-K	Current Report
Sep 01, 2023	4	Insider Trading
Aug 31, 2023	8-K	Current Report

Peers (Alternatives to Adaptimmune Therapeutics Plc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
HILS	32.8B	-	14.55%	467931.97%	-3.8K	218.4K	-	-102.45%
MRNA	29.6B	10.7B	8.07%	-55.95%	-8.54	2.78	-53.67%	-129.46%
ALNY	20.0B	1.7B	4.90%	-25.16%	-39.17	11.59	79.37%	56.87%
BMRN	16.7B	2.3B	9.83%	-8.58%	113.5	7.22	15.05%	75.21%
INCY	11.8B	3.6B	0.63%	-32.44%	27.88	3.28	8.35%	-51.49%
MID-CAP
APLS	5.7B	272.9M	1.64%	-5.18%	-9.43	20.95	141.38%	4.43%
BBIO	5.2B	-	21.89%	247.20%	-8.88	48.33	54.84%	-12.96%
ACAD	3.6B	631.9M	1.65%	46.39%	-24.37	5.74	23.54%	31.53%
AXSM	3.1B	223.4M	6.77%	16.65%	-15.53	14.03	-	-26.24%
ARWR	3.1B	256.2M	21.69%	-2.64%	-16.98	12	2.51%	-17.66%
SMALL-CAP
CPRX	1.5B	348.4M	17.40%	-16.91%	24.23	4.31	81.69%	-7.29%
NVAX	648.3M	1.0B	-14.02%	-66.99%	-1.18	0.62	-43.15%	58.48%
INO	108.4M	6.4M	10.81%	-79.60%	-0.66	16.83	-44.11%	50.48%
CRBP	18.7M	-	-19.00%	3569.57%	-0.39	-	-	-13.74%
IBIO	8.0M	-	-	-82.21%	-0.12	-	-	-29.23%

Adaptimmune Therapeutics Plc News

Latest updates

Financials for Adaptimmune Therapeutics Plc

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	42.7%	7,319,000	5,130,000	47,601,000	11,028,000	7,007,000	5,538,000	3,575,000	1,417,000	1,203,000	3,095,000	434,000	1,502,000	1,193,000	502,000	761,000	728,000	237,000	651,000	1,065,000	1,479,000	40,792,000
Costs and Expenses	7.8%	53,952,000	50,038,000	45,945,000	38,270,000	49,997,000	49,290,000	53,556,000	44,281,000	43,384,000	42,407,000	38,323,000	39,015,000	37,068,000	30,755,000	30,525,000	31,083,000	40,358,000	35,659,000	33,792,000	33,415,000	33,774,000
S&GA Expenses	-19.5%	16,164,000	20,073,000	20,397,000	15,218,000	16,815,000	14,550,000	16,804,000	14,776,000	15,173,000	13,539,000	13,817,000	13,238,000	13,001,000	10,295,000	9,261,000	10,729,000	10,741,000	10,148,000	11,773,000	10,816,000	10,290,000
R&D Expenses	26.1%	37,788,000	29,965,000	25,548,000	23,052,000	33,182,000	34,740,000	36,752,000	29,505,000	28,211,000	28,868,000	24,506,000	25,777,000	24,067,000	20,460,000	21,264,000	20,354,000	29,617,000	25,511,000	22,019,000	22,599,000	23,484,000
EBITDA Margin	100.0%	-	-1.16	-1.49	-5.81	-9.58	-14.41	-17.64	-24.67	-23.97	-22.90	-38.36	-32.83	-38.52	-56.75	-82.16	-122	-	-	-	-	-
Income Taxes	1.0%	687,000	680,000	625,000	994,000	399,000	470,000	634,000	209,000	208,000	76,000	298,000	52,000	15,000	25,000	70,000	88,000	87,000	65,000	2,000	135,000	133,000
Earnings Before Taxes	-116.9%	-44,914,000	-20,709,000	1,661,000	-28,256,000	-41,022,000	-44,050,000	-49,631,000	-38,649,000	-42,193,000	-38,992,000	-37,465,000	-36,561,000	-35,417,000	-29,855,000	-28,097,000	-29,276,000	-39,215,000	-41,022,000	-27,410,000	-35,868,000	5,375,000
EBT Margin	100.0%	-	-1.25	-1.57	-6.00	-9.88	-14.87	-18.24	-25.58	-24.90	-23.85	-38.36	-32.83	-38.52	-56.75	-82.16	-122	-	-	-	-	-
Net Income	-113.2%	-45,601,000	-21,389,000	1,036,000	-29,250,000	-41,421,000	-44,520,000	-50,265,000	-38,858,000	-42,401,000	-39,068,000	-37,763,000	-36,613,000	-35,432,000	-29,880,000	-28,167,000	-29,364,000	-39,302,000	-41,087,000	-27,412,000	-36,173,000	5,242,000
Net Income Margin	100.0%	-	-1.29	-1.60	-6.09	-9.98	-15.00	-18.36	-25.71	-25.00	-23.92	-38.47	-32.87	-38.58	-56.87	-82.34	-122	-	-	-	-	-
Free Cashflow	100.0%	-	-44,978,000	-39,632,000	-1,373,000	-58,166,000	-50,211,000	-61,515,000	129,912,000	-46,834,000	-33,231,000	-47,692,000	-30,383,000	-17,031,000	-25,183,000	16,665,000	-12,688,000	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	-13.5%	297	343	288	329	332	388	420	470	354	390	412	451	479	512	285	182	208	240	270	277	310
Current Assets	-16.2%	219	262	214	255	264	321	359	415	300	337	359	398	427	458	228	120	147	175	200	231	262
Cash Equivalents	20.9%	93.00	77.00	120	108	79.00	100	91.00	152	45.00	55.00	37.00	61.00	83.00	127	91.00	55.00	44.00	39.00	54.00	72.00	157
Net PPE	-5.3%	53.00	55.00	54.00	54.00	48.00	45.00	37.00	30.00	29.00	29.00	28.00	28.00	27.00	27.00	29.00	31.00	32.00	34.00	36.00	36.00	38.00
Liabilities	-3.6%	209	216	204	247	219	246	257	264	113	112	102	110	103	105	99.00	58.00	61.00	53.00	51.00	30.00	33.00
Current Liabilities	-1.3%	75.00	76.00	64.00	65.00	66.00	74.00	66.00	63.00	41.00	41.00	31.00	39.00	35.00	39.00	30.00	34.00	37.00	28.00	23.00	24.00	30.00
Shareholder's Equity	-30.4%	88.00	127	84.00	82.00	113	142	163	206	241	278	309	341	376	408	186	124	148	187	220	247	276
Retained Earnings	-4.9%	-975	-929	-908	-909	-880	-838	-794	-743	-704	-662	-623	-585	-549	-513	-483	-455	-426	-387	-345	-318	-282
Additional Paid-In Capital	0.4%	1,061	1,058	993	991	985	980	965	960	955	950	942	936	933	929	678	586	583	581	578	574	570
Accumulated Depreciation	4.7%	43.00	41.00	39.00	39.00	35.00	36.00	37.00	36.00	35.00	34.00	33.00	31.00	29.00	26.00	24.00	24.00	21.00	20.00	18.00	16.00	-
Shares Outstanding	0.7%	1,362	1,352	994	987	983	963	940	929	937	934	931	929	928	781	740	631	629	629	628	584	582

Cashflow (Last 12 Months)
(In Millions)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	-3.2%	-45,159	-43,762	-37,283	2,042	-48,159	-41,251	-54,401	133,928	-45,200	-31,459	-46,540	-29,216	-16,317	-24,915	16,857	-12,528	-29,608	-34,168	-36,203	-31,685	9,939
Share Based Compensation	-17.1%	3,179	3,837	1,676	3,946	3,663	5,045	5,586	4,827	5,019	5,449	5,334	3,062	3,280	2,624	1,448	2,558	1,820	3,196	3,479	3,749	4,042
Cashflow From Investing	2027.2%	57,306	2,694	48,341	20,952	28,851	44,109	-4,775	-28,491	34,851	47,678	21,762	7,608	-27,580	-187,005	-71,947	23,683	35,045	18,561	17,656	-52,411	942
Cashflow From Financing	4157.1%	596	14.00	196	1,403	1,452	9,977	35.00	52.00	139	2,563	534	122	466	248,019	91,444	-	-	330	36.00	104	100,162

ADAP Income Statement

2023-09-30

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 7,319,000	$ 7,007,000	$ 60,050,000	$ 16,120,000
Operating expenses
Research and development	(37,788,000)	(33,182,000)	(93,301,000)	(104,674,000)
General and administrative	(16,164,000)	(16,815,000)	(56,634,000)	(48,169,000)
Total operating expenses	(53,952,000)	(49,997,000)	(149,935,000)	(152,843,000)
Operating loss	(46,633,000)	(42,990,000)	(89,885,000)	(136,723,000)
Interest income	2,149,000	324,000	4,368,000	1,019,000
Gain on bargain purchase			22,049,000
Remeasurement on bargain purchase	(106,000)
Other income (expense), net	(324,000)	1,644,000	(494,000)	1,001,000
Loss before income tax expense	(44,914,000)	(41,022,000)	(63,962,000)	(134,703,000)
Income tax expense	(687,000)	(399,000)	(1,992,000)	(1,503,000)
Net loss attributable to ordinary shareholders	$ (45,601,000)	$ (41,421,000)	$ (65,954,000)	$ (136,206,000)
Net loss per ordinary share
Basic (in dollars per share)	$ (0.03)	$ (0.04)	$ (0.06)	$ (0.14)
Diluted (in dollars per share)	$ (0.03)	$ (0.04)	$ (0.06)	$ (0.14)
Weighted average shares outstanding:
Basic (in shares)	1,357,849,656	980,791,114	1,153,791,567	961,354,122
Diluted (in shares)	1,357,849,656	980,791,114	1,153,791,567	961,354,122

ADAP Balance Sheet

2023-09-30

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 90,059,000	$ 108,033,000
Marketable securities - available-for-sale debt securities	71,669,000	96,572,000
Accounts receivable, net of allowance for expected credit losses of $0 and $0	789,000	7,435,000
Other current assets and prepaid expenses	56,851,000	43,330,000
Total current assets	219,368,000	255,370,000
Restricted cash	3,013,000	1,569,000
Operating lease right-of-use assets, net of accumulated amortization of $11,930 and $9,470	21,302,000	18,019,000
Property, plant and equipment, net of accumulated depreciation of $42,543 and $38,588	52,571,000	53,516,000
Intangible assets, net of accumulated amortization of $5,008 and $4,676	384,000	442,000
Total assets	296,638,000	328,916,000
Current liabilities
Accounts payable	13,922,000	4,753,000
Operating lease liabilities, current	5,081,000	2,728,000
Accrued expenses and other current liabilities	26,831,000	31,215,000
Restructuring provision		2,285,000
Deferred revenue, current	29,312,000	23,520,000
Total current liabilities	75,146,000	64,501,000
Operating lease liabilities, non-current	20,520,000	20,349,000
Deferred revenue, non-current	111,487,000	160,892,000
Other liabilities, non-current	1,356,000	1,296,000
Total liabilities	208,509,000	247,038,000
Stockholders' equity
Common stock - Ordinary shares par value £0.001, 1,702,760,280 authorized and 1,361,595,036 issued and outstanding (2022: 1,282,773,750 authorized and 987,109,890 issued and outstanding)	1,863,000	1,399,000
Additional paid in capital	1,061,420,000	990,656,000
Accumulated other comprehensive gain/(loss)	102,000	(875,000)
Accumulated deficit	(975,256,000)	(909,302,000)
Total stockholders' equity	88,129,000	81,878,000
Total liabilities and stockholders' equity	$ 296,638,000	$ 328,916,000

About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

CEO	Mr. Adrian G. Rawcliffe
WEBSITE	www.adaptimmune.com
EMPLOYEES	534

Adaptimmune Therapeutics Plc Frequently Asked Questions

What is the ticker symbol for Adaptimmune Therapeutics Plc?

Ticker symbol for Adaptimmune Therapeutics Plc is ADAP.

What is the market capital of Adaptimmune Therapeutics Plc (ADAP)?

As of Mon Nov 27 2023, market cap of Adaptimmune Therapeutics Plc is 653.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADAP stock?

You can check ADAP's fair value in chart. The fair value of Adaptimmune Therapeutics Plc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adaptimmune Therapeutics Plc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADAP so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Adaptimmune Therapeutics Plc stock overpriced or underpriced?

The fair value guage provides a quick view whether ADAP is over valued or under valued. Whether Adaptimmune Therapeutics Plc is cheap or expensive depends on the assumptions which impact Adaptimmune Therapeutics Plc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADAP.

What is Adaptimmune Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 27 2023, ADAP's PE ratio (Price to Earnings) is -6.86 and Price to Sales (PS) ratio is 9.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADAP PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

ADAP Alerts

ADAP Stock Price

ADAP RSI Chart

ADAP Alerts

ADAP Valuation

ADAP Price/Sales (Trailing)

ADAP Profitability

ADAP Fundamentals

ADAP Revenue

ADAP Earnings

Price Action

How does ADAP drawdown profile look like?

ADAP Financial Health

ADAP Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for ADAP

Which funds bought or sold ADAP recently?

Latest Funds Activity

Schedule 13G FIlings of Adaptimmune Therapeutics Plc

Recent SEC filings of Adaptimmune Therapeutics Plc

Peers (Alternatives to Adaptimmune Therapeutics Plc)

Adaptimmune Therapeutics Plc News

Financials for Adaptimmune Therapeutics Plc

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Millions)

ADAP Income Statement

ADAP Balance Sheet

About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc Frequently Asked Questions

What is the ticker symbol for Adaptimmune Therapeutics Plc?

What is the market capital of Adaptimmune Therapeutics Plc (ADAP)?

What is the fair value of ADAP stock?

Is Adaptimmune Therapeutics Plc stock overpriced or underpriced?

What is Adaptimmune Therapeutics Plc's Price to Earnings (PE) and Price to sales (PS) ratio?

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)